Park City Bio

Park City Bio is a biotechnology company advancing a focused portfolio of patented drug candidates. We are currently completing IND studies on two of our lead compounds and will complete Phase I trials on each drug in 2027. Thereafter, we will enter Phase II studies targeting epilepsy, obesity, alcohol use disorder (AUD) and methamphetamine use disorder (MUD).